Targeting Notch Signaling for Cancer Therapeutic Intervention

Advances in Pharmacology

Volumn 65, Issue , 2012, Pages 191-234

  Shao, Hongwei ^a   Huang, Qinghua ^a   Liu, Zhao Jun ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Cancer; Cancer therapeutics; Notch; Signal transduction; Tumor; Tumor angiogenesis

Indexed keywords

ANTINEOPLASTIC AGENT; COREPRESSOR PROTEIN; DOXORUBICIN; GAMMA SECRETASE INHIBITOR; GEMCITABINE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; JAGGED1; LETROZOLE; MK 0752; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; ONCOPROTEIN; PF 3084014; SARCOLYSIN; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER STEM CELL; CARCINOGENESIS; CELL FATE; CELL TRANSFORMATION; COLORECTAL CANCER; COMPLEX FORMATION; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GENE TARGETING; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; KAPOSI SARCOMA; LEUKEMIA; LIVER CELL CARCINOMA; LYMPHOMA; MORPHOGENESIS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; STROMA CELL; TRANSCRIPTION INITIATION;

EID: 84865858012     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397927-8.00007-5     Document Type: Chapter

References (210)

1. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
2. Amsen D., Antov A., Jankovic D., Sher A., Radtke F., Souabni A., et al. Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity 2007, 27:89-99.
3. Androutsellis-Theotokis A., Leker R.R., Soldner F., Hoeppner D.J., Ravin R., Poser S.W., et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006, 442:823-826.
4. Anton K., Glod J. Targeting the tumor stroma in cancer therapy. Current Pharmaceutical Biotechnology 2009, 10:185-191.
5. Arora P.S., Ansari A.Z. Chemical biology: a Notch above other inhibitors. Nature 2009, 462:171-173.
6. Balint K., Xiao M., Pinnix C.C., Soma A., Veres I., Juhasz I., et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. The Journal of Clinical Investigation 2005, 115:3166-3176.
7. Barten D.M., Meredith J.E., Zaczek R., Houston J.G., Albright C.F. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs in R&D 2006, 7:87-97.
8. Bedogni B., Warneke J.A., Nickoloff B.J., Giaccia A.J., Powell M.B. Notch1 is an effector of Akt and hypoxia in melanoma development. The Journal of Clinical Investigation 2008, 118:3660-3670.
9. Berg J.W., Lampe J.G. High-risk factors in gynecologic cancer. Cancer 1981, 48:429-441.
10. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
11. Blaumueller C.M., Qi H., Zagouras P., Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 1997, 90:281-291.
12. Bozkulak E.C., Weinmaster G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Molecular and Cellular Biology 2009, 29:5679-5695.
13. Brou C., Logeat F., Gupta N., Bessia C., LeBail O., Doedens J.R., et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Molecular Cell 2000, 5:207-216.
14. Bruckner K., Perez L., Clausen H., Cohen S. Glycosyltransferase activity of Fringe modulates Notch-delta interactions. Nature 2000, 406:411-415.
15. Callahan R., Egan S.E. Notch signaling in mammary development and oncogenesis. Journal of Mammary Gland Biology and Neoplasia 2004, 9:145-163.
16. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
17. Chan S.M., Weng A.P., Tibshirani R., Aster J.C., Utz P.J. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007, 110:278-286.
18. Chen Y., De Marco M.A., Graziani I., Gazdar A.F., Strack P.R., Miele L., et al. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Research 2007, 67:7954-7959.
19. Cheng P., Zlobin A., Volgina V., Gottipati S., Osborne B., Simel E.J., et al. Notch-1 regulates NF-kappaB activity in hemopoietic progenitor cells. The Journal of Immunology 2001, 167:4458-4467.
20. Chiaramonte R., Basile A., Tassi E., Calzavara E., Cecchinato V., Rossi V., et al. A wide role for NOTCH1 signaling in acute leukemia. Cancer Letters 2005, 219:113-120.
21. Clarke R.B., Spence K., Anderson E., Howell A., Okano H., Potten C.S. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Developmental Biology 2005, 277:443-456.
22. Cohen B., Shimizu M., Izrailit J., Ng N.F., Buchman Y., Pan J.G., et al. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Research and Treatment 2009, 123:113-124.
23. Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 230:1132-1139.
24. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15:21-34.
25. Croquelois A., Blindenbacher A., Terracciano L., Wang X., Langer I., Radtke F., et al. Inducible inactivation of Notch1 causes nodular regenerative hyperplasia in mice. Hepatology 2005, 41:487-496.
26. Curry C.L., Reed L.L., Golde T.E., Miele L., Nickoloff B.J., Foreman K.E. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 2005, 24:6333-6344.
27. De Koning L., Corpet A., Haber J.E., Almouzni G. Histone chaperones: an escort network regulating histone traffic. Nature Structural & Molecular Biology 2007, 14:997-1007.
28. De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999, 398:518-522.
29. Deftos M.L., Huang E., Ojala E.W., Forbush K.A., Bevan M.J. Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. Immunity 2000, 13:73-84.
30. Delwig A., Rand M.D. Kuz and TACE can activate Notch independent of ligand. Cellular and Molecular Life Science 2008, 65:2232-2243.
31. Demehri S., Turkoz A., Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 2009, 16:55-66.
32. Dievart A., Beaulieu N., Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 1999, 18:5973-5981.
33. Dufraine J., Funahashi Y., Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008, 27:5132-5137.
34. Eitoku M., Sato L., Senda T., Horikoshi M. Histone chaperones: 30 years from isolation to elucidation of the mechanisms of nucleosome assembly and disassembly. Cellular and Molecular Life Science 2008, 65:414-444.
35. Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D., et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66:649-661.
36. Espinosa L., Ingles-Esteve J., Aguilera C., Bigas A. Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. The Journal of Biological Chemistry 2003, 278:32227-32235.
37. Fan X., Khaki L., Zhu T.S., Soules M.E., Talsma C.E., Gul N., et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010, 28:5-16.
38. Fan X., Mikolaenko I., Elhassan I., Ni X., Wang Y., Ball D., et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Research 2004, 64:7787-7793.
39. Ferrara N., Clapp C., Weiner R. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991, 129:896-900.
40. Fontana J.R., Posakony J.W. Both inhibition and activation of Notch signaling rely on a conserved neuralized-binding motif in bearded proteins and the Notch ligand Delta. Developmental Biology 2009, 333:373-385.
41. Fu L., Kogoshi H., Nara N., Tohda S. NOTCH1 mutations are rare in acute myeloid leukemia. Leukemia & Lymphoma 2006, 47:2400-2403.
42. Fung E., Tang S.M., Canner J.P., Morishige K., Arboleda-Velasquez J.F., Cardoso A.A., et al. Delta-like 4 induces notch signaling in macrophages: implications for inflammation. Circulation 2007, 115:2948-2956.
43. Gal H., Amariglio N., Trakhtenbrot L., Jacob-Hirsh J., Margalit O., Avigdor A., et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006, 20:2147-2154.
44. Gale N.W., Dominguez M.G., Noguera I., Pan L., Hughes V., Valenzuela D.M., et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:15949-15954.
45. Gallahan D., Callahan R. Mammary tumorigenesis in feral mice: identification of a new int locus in mouse mammary tumor virus (Czech II)-induced mammary tumors. Journal of Virology 1987, 61:66-74.
46. Garzia L., Andolfo I., Cusanelli E., Marino N., Petrosino G., De Martino D., et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 2009, 4:e4998.
47. Goodfellow H., Krejci A., Moshkin Y., Verrijzer C.P., Karch F., Bray S.J. Gene-specific targeting of the histone chaperone asf1 to mediate silencing. Developmental Cell 2007, 13:593-600.
48. Goodlad R.A., Ryan A.J., Wedge S.R., Pyrah I.T., Alferez D., Poulsom R., et al. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis 2006, 27:2133-2139.
49. Gupta A., Wang Y., Browne C., Kim S., Case T., Paul M., et al. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Prostate 2008, 68:50-60.
50. Haines N., Irvine K.D. Glycosylation regulates Notch signalling. Nature Reviews Molecular Cell Biology 2003, 4:786-797.
51. Hallahan A.R., Pritchard J.I., Hansen S., Benson M., Stoeck J., Hatton B.A., et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Research 2004, 64:7794-7800.
52. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
53. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
54. Haruki N., Kawaguchi K.S., Eichenberger S., Massion P.P., Olson S., Gonzalez A., et al. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Research 2005, 65:3555-3561.
55. Hayward S.W., Wang Y., Cao M., Hom Y.K., Zhang B., Grossfeld G.D., et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Research 2001, 61:8135-8142.
56. He F., Saito K., Kobayashi N., Harada T., Watanabe S., Kigawa T., et al. Structural and functional characterization of the NHR1 domain of the Drosophila neuralized E3 ligase in the notch signaling pathway. Journal of Molecular Biology 2009, 393:478-495.
57. Hoey T., Yen W.C., Axelrod F., Basi J., Donigian L., Dylla S., et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
58. Hopfer O., Zwahlen D., Fey M.F., Aebi S. The Notch pathway in ovarian carcinomas and adenomas. British Journal of Cancer 2005, 93:709-718.
59. Hu C., Dievart A., Lupien M., Calvo E., Tremblay G., Jolicoeur P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. The American Journal of Pathology 2006, 168:973-990.
60. Indraccolo S., Minuzzo S., Masiero M., Pusceddu I., Persano L., Moserle L., et al. Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Research 2009, 69:1314-1323.
61. Iso T., Kedes L., Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. Journal of Cellular Physiology 2003, 194:237-255.
62. Izon D.J., Aster J.C., He Y., Weng A., Karnell F.G., Patriub V., et al. Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1. Immunity 2002, 16:231-243.
63. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer Journal of Clincians 2009, 59:225-249.
64. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer Journal of Clincians 2010, 60:277-300.
65. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PloS One 2009, 4:e6816.
66. Jin Y.H., Kim H., Oh M., Ki H., Kim K. Regulation of Notch1/NICD and Hes1 expressions by GSK-3alpha/beta. Molecules and Cells 2009, 27:15-19.
67. Jubb A.M., Turley H., Moeller H.C., Steers G., Han C., Li J.L., et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. British Journal of Cancer 2009, 101:1749-1757.
68. Jundt F., Anagnostopoulos I., Forster R., Mathas S., Stein H., Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002, 99:3398-3403.
69. Jundt F., Probsting K.S., Anagnostopoulos I., Muehlinghaus G., Chatterjee M., Mathas S., et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004, 103:3511-3515.
70. Kallifatidis G., Labsch S., Rausch V., Mattern J., Gladkich J., Moldenhauer G., et al. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Molecular Therapy 2011, 19:188-195.
71. Kawahara T., Kawaguchi-Ihara N., Okuhashi Y., Itoh M., Nara N., Tohda S. Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells. Anticancer Research 2009, 29:4629-4632.
72. Kidd S., Baylies M.K., Gasic G.P., Young M.W. Structure and distribution of the Notch protein in developing Drosophila. Genes & Development 1989, 3:1113-1129.
73. Kidd S., Lieber T., Young M.W. Ligand-induced cleavage and regulation of nuclear entry of Notch in Drosophila melanogaster embryos. Genes & Development 1998, 12:3728-3740.
74. Kim S.H., Sehrawat A., Sakao K., Hahm E.R., Singh S.V. Notch activation by phenethyl isothiocyanate attenuates its inhibitory effect on prostate cancer cell migration. PLoS One 2012, 6. e26615.
75. Konishi J., Yi F., Chen X., Vo H., Carbone D.P., Dang T.P. Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene 2010, 29:589-596.
76. Kopan R., Nye J.S., Weintraub H. The intracellular domain of mouse Notch: a constitutively activated repressor of myogenesis directed at the basic helix-loop-helix region of MyoD. Development 1994, 120:2385-2396.
77. Korsisaari N., Kasman I.M., Forrest W.F., Pal N., Bai W., Fuh G., et al. Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:10625-10630.
78. Krebs L.T., Shutter J.R., Tanigaki K., Honjo T., Stark K.L., Gridley T. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes & Development 2004, 18:2469-2473.
79. Lai E.C. Protein degradation: four E3s for the notch pathway. Current Biology 2002, 12:R74-78.
80. Lamar E., Deblandre G., Wettstein D., Gawantka V., Pollet N., Niehrs C., et al. Nrarp is a novel intracellular component of the Notch signaling pathway. Genes & Development 2001, 15:1885-1899.
81. Lan K., Murakami M., Choudhuri T., Kuppers D.A., Robertson E.S. Intracellular-activated Notch1 can reactivate Kaposi's sarcoma-associated herpesvirus from latency. Virology 2006, 351:393-403.
82. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
83. Le Borgne R., Remaud S., Hamel S., Schweisguth F. Two distinct E3 ubiquitin ligases have complementary functions in the regulation of delta and serrate signaling in Drosophila. PLoS Biology 2005, 3:e96.
84. Lee S.Y., Kumano K., Nakazaki K., Sanada M., Matsumoto A., Yamamoto G., et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Science 2009, 100:920-926.
85. Leong K.G., Gao W.Q. The Notch pathway in prostate development and cancer. Differentiation 2008, 76:699-716.
86. Lewis H.D., Leveridge M., Strack P.R., Haldon C.D., O'Neil J., Kim H., et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chemistry & Biology 2007, 14:209-219.
87. Li J.L., Sainson R.C., Shi W., Leek R., Harrington L.S., Preusser M., et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Research 2007, 67:11244-11253.
88. Li K., Li Y., Wu W., Gordon W.R., Chang D.W., Lu M., et al. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. The Journal of Biological Chemistry 2008, 283:8046-8054.
89. Li Y., Guessous F., Zhang Y., Dipierro C., Kefas B., Johnson E., et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Research 2009, 69:7569-7576.
90. Lichtenthaler S.F., Ida N., Multhaup G., Masters C.L., Beyreuther K. Mutations in the transmembrane domain of APP altering gamma-secretase specificity. Biochemistry 1997, 36:15396-15403.
91. Liu Z.J., Shirakawa T., Li Y., Soma A., Oka M., Dotto G.P., et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Molecular and Cellular Biology 2003, 23:14-25.
92. Liu Z.J., Xiao M., Balint K., Smalley K.S., Brafford P., Qiu R., et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Research 2006, 66:4182-4190.
93. Liu Z.J., Zhuge Y., Velazquez O.C. Trafficking and differentiation of mesenchymal stem cells. Journal of Cell Biochemistry 2009, 106:984-991.
94. Lleo A. Activity of gamma-secretase on substrates other than APP. Current Topics in Medicinal Chemistry 2008, 8:9-16.
95. Lobov I.B., Renard R.A., Papadopoulos N., Gale N.W., Thurston G., Yancopoulos G.D., et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:3219-3224.
96. Lorusso G., Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochemistry and Cell Biology 2008, 130:1091-1103.
97. Luistro L., He W., Smith M., Packman K., Vilenchik M., Carvajal D., et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Research 2009, 69:7672-7680.
98. Lynch C.C., Matrisian L.M. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002, 70:561-573.
99. Ma J., Meng Y., Kwiatkowski D.J., Chen X., Peng H., Sun Q. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. The Journal of Clinical Investigation 2010, 120:103-114.
100. Maillard I., Adler S.H., Pear W.S. Notch and the immune system. Immunity 2003, 19:781-791.
101. Maillard I., Weng A.P., Carpenter A.C., Rodriguez C.G., Sai H., Xu L., et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood 2004, 104:1696-1702.
102. Mamaeva O.A., Kim J., Feng G., McDonald J.M. Calcium/calmodulin-dependent kinase II regulates notch-1 signaling in prostate cancer cells. Journal of Cell Biochemistry 2009, 106:25-32.
103. Martinez A.M., Schuettengruber B., Sakr S., Janic A., Gonzalez C., Cavalli G. Polyhomeotic has a tumor suppressor activity mediated by repression of Notch signaling. Nature Genetics 2009, 41:1076-1082.
104. Martinez Arias A., Zecchini V., Brennan K. CSL-independent Notch signalling: a checkpoint in cell fate decisions during development?. Current Opinion in Genetic and Development 2002, 12:524-533.
105. Masuda S., Kumano K., Suzuki T., Tomita T., Iwatsubo T., Natsugari H., et al. Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model. Cancer Science 2009, 100:2444-2450.
106. Masumori N., Thomas T.Z., Chaurand P., Case T., Paul M., Kasper S., et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Research 2001, 61:2239-2249.
107. Meng R.D., Shelton C.C., Li Y.M., Qin L.X., Notterman D., Paty P.B., et al. Gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Research 2009, 69:573-582.
108. Midwood K.S., Williams L.V., Schwarzbauer J.E. Tissue repair and the dynamics of the extracellular matrix. The International Journal of Biochemistry & Cell Biology 2004, 36:1031-1037.
109. Miyamoto Y., Maitra A., Ghosh B., Zechner U., Argani P., Iacobuzio-Donahue C.A., et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003, 3:565-576.
110. Moellering R.E., Cornejo M., Davis T.N., Del Bianco C., Aster J.C., Blacklow S.C., et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009, 462:182-188.
111. Moshkin Y.M., Kan T.W., Goodfellow H., Bezstarosti K., Maeda R.K., Pilyugin M., et al. Histone chaperones ASF1 and NAP1 differentially modulate removal of active histone marks by LID-RPD3 complexes during NOTCH silencing. Molecular Cell 2009, 35:782-793.
112. Mukherjee S., Schaller M.A., Neupane R., Kunkel S.L., Lukacs N.W. Regulation of T cell activation by Notch ligand, DLL4, promotes IL-17 production and Rorc activation. The Journal of Immunology 2009, 182:7381-7388.
113. Mullendore M.E., Koorstra J.B., Li Y.M., Offerhaus G.J., Fan X., Henderson C.M., et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clinical Cancer Research 2009, 15:2291-2301.
114. Mumm J.S., Schroeter E.H., Saxena M.T., Griesemer A., Tian X., Pan D.J., et al. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Molecular Cell 2000, 5:197-206.
115. Nagaraj R., Banerjee U. Regulation of Notch and wingless signalling by phyllopod, a transcriptional target of the EGFR pathway. The EMBO Journal 2009, 28:337-346.
116. Nakayama K., Nakayama N., Jinawath N., Salani R., Kurman R.J., Shih Ie M., et al. Amplicon profiles in ovarian serous carcinomas. International Journal of Cancer 2007, 120:2613-2617.
117. Nam Y., Sliz P., Song L., Aster J.C., Blacklow S.C. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 2006, 124:973-983.
118. Nefedova Y., Cheng P., Alsina M., Dalton W.S., Gabrilovich D.I. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004, 103:3503-3510.
119. Nefedova Y., Sullivan D.M., Bolick S.C., Dalton W.S., Gabrilovich D.I. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008, 111:2220-2229.
120. Nicolas M., Wolfer A., Raj K., Kummer J.A., Mill P., van Noort M., et al. Notch1 functions as a tumor suppressor in mouse skin. Nature Genetics 2003, 33:416-421.
121. Nie J., McGill M.A., Dermer M., Dho S.E., Wolting C.D., McGlade C.J. LNX functions as a RING type E3 ubiquitin ligase that targets the cell fate determinant numb for ubiquitin-dependent degradation. The EMBO Journal 2002, 21:93-102.
122. Noguera-Troise I., Daly C., Papadopoulos N.J., Coetzee S., Boland P., Gale N.W., et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444:1032-1037.
123. O'Neil J., Calvo J., McKenna K., Krishnamoorthy V., Aster J.C., Bassing C.H., et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 2006, 107:781-785.
124. O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter C., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. The Journal of Experimental Medicine 2007, 204:1813-1824.
125. Okajima T., Irvine K.D. Regulation of notch signaling by o-linked fucose. Cell 2002, 111:893-904.
126. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Research 1999, 59:5002-5011.
127. Ono Y., Gnocchi V.F., Zammit P.S., Nagatomi R. Presenilin-1 acts via Id1 to regulate the function of muscle satellite cells in a gamma-secretase-independent manner. Journal of Cell Science 2009, 122:4427-4438.
128. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
129. Orimo A., Weinberg R.A. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601.
130. Osipo C., Patel P., Rizzo P., Clementz A.G., Hao L., Golde T.E., et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008, 27:5019-5032.
131. Palomero T., Dominguez M., Ferrando A.A. The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 2008, 7:965-970.
132. Palomero T., McKenna K.J.O.N., Galinsky I., Stone R., Suzukawa K., Stiakaki E., et al. Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia 2006, 20:1963-1966.
133. Palomero T., Sulis M.L., Cortina M., Real P.J., Barnes K., Ciofani M., et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Medicine 2007, 13:1203-1210.
134. Park J.T., Li M., Nakayama K., Mao T.L., Davidson B., Zhang Z., et al. Notch3 gene amplification in ovarian cancer. Cancer Research 2006, 66:6312-6318.
135. Parkin D.M. Cancer in developing countries. Cancer Surveys 1994, 19-20:519-561.
136. Parr C., Watkins G., Jiang W.G. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. International Journal of Molecular Medicine 2004, 14:779-786.
137. Patel N.S., Li J.L., Generali D., Poulsom R., Cranston D.W., Harris A.L. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Research 2005, 65:8690-8697.
138. Pece S., Serresi M., Santolini E., Capra M., Hulleman E., Galimberti V., et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. The Journal of Cell Biology 2004, 167:215-221.
139. Phillips T.M., Kim K., Vlashi E., McBride W.H., Pajonk F. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 2007, 9:1122-1129.
140. Pierfelice T.J., Schreck K.C., Eberhart C.G., Gaiano N. Notch, neural stem cells, and brain tumors. Cold Spring Harbor Symposia in Quantitative Biology 2008, 73:367-375.
141. Pillai R.S., Bhattacharyya S.N., Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms?. Trends in Cell Biology 2007, 17:118-126.
142. Pinnix C.C., Lee J.T., Liu Z.J., McDaid R., Balint K., Beverly L.J., et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Research 2009, 69:5312-5320.
143. Proweller A., Tu L., Lepore J.J., Cheng L., Lu M.M., Seykora J., et al. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Research 2006, 66:7438-7444.
144. Qi R., An H., Yu Y., Zhang M., Liu S., Xu H., et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Research 2003, 63:8323-8329.
145. Raafat A., Bargo S., Anver M.R., Callahan R. Mammary development and tumorigenesis in mice expressing a truncated human Notch4/Int3 intracellular domain (h-Int3sh). Oncogene 2004, 23:9401-9407.
146. Radtke F., Fasnacht N., Macdonald H.R. Notch signaling in the immune system. Immunity 2010, 32:14-27.
147. Radtke F., Wilson A., Stark G., Bauer M., van Meerwijk J., MacDonald H.R., et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999, 10:547-558.
148. Rangarajan A., Talora C., Okuyama R., Nicolas M., Mammucari C., Oh H., et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. The EMBO Journal 2001, 20:3427-3436.
149. Rasul S., Balasubramanian R., Filipovic A., Slade M.J., Yague E., Coombes R.C. Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. British Journal of Cancer 2009, 100:1879-1888.
150. Real P.J., Tosello V., Palomero T., Castillo M., Hernando E., de Stanchina E., et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nature Medicine 2009, 15:50-58.
151. Reedijk M., Odorcic S., Chang L., Zhang H., Miller N., McCready D.R., et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Research 2005, 65:8530-8537.
152. Reedijk M., Odorcic S., Zhang H., Chetty R., Tennert C., Dickson B.C., et al. Activation of Notch signaling in human colon adenocarcinoma. International Journal of Oncology 2008, 33:1223-1229.
153. Reizis B., Leder P. Direct induction of T lymphocyte-specific gene expression by the mammalian Notch signaling pathway. Genes & Development 2002, 16:295-300.
154. Ridgway J., Zhang G., Wu Y., Stawicki S., Liang W.C., Chanthery Y., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444:1083-1087.
155. Robinson D.R., Kalyana-Sundaram S., Wu Y.M., Shankar S., Cao X., Ateeq B., et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Medicine 2011, 17:1646-1651.
156. Ronchini C., Capobianco A.J. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Molecular and Cellular Biology 2001, 21:5925-5934.
157. Rosati E., Sabatini R., Rampino G., Tabilio A., Di Ianni M., Fettucciari K., et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009, 113:856-865.
158. Rose S.L., Kunnimalaiyaan M., Drenzek J., Seiler N. Notch 1 signaling is active in ovarian cancer. Gynecologic Oncology 2010, 117:130-133.
159. Sakata T., Sakaguchi H., Tsuda L., Higashitani A., Aigaki T., Matsuno K., et al. Drosophila Nedd4 regulates endocytosis of notch and suppresses its ligand-independent activation. Current Biology 2004, 14:2228-2236.
160. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. The Journal of Clinical Investigation 2007, 117:3988-4002.
161. Santagata S., Demichelis F., Riva A., Varambally S., Hofer M.D., Kutok J.L., et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Research 2004, 64:6854-6857.
162. Sawey E.T., Johnson J.A., Crawford H.C. Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:19327-19332.
163. Scehnet J.S., Jiang W., Kumar S.R., Krasnoperov V., Trindade A., Benedito R., et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007, 109:4753-4760.
164. Schroeter E.H., Kisslinger J.A., Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998, 393:382-386.
165. Schuettengruber B., Chourrout D., Vervoort M., Leblanc B., Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell 2007, 128:735-745.
166. Shao H., Cai L., Grichnik J.M., Livingstone A.S., Velazquez O.C., Liu Z.J. Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene 2011, 30:4316-4326.
167. Shelton C.C., Zhu L., Chau D., Yang L., Wang R., Djaballah H., et al. Modulation of gamma-secretase specificity using small molecule allosteric inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:20228-20233.
168. Shou J., Ross S., Koeppen H., de Sauvage F.J., Gao W.Q. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Research 2001, 61:7291-7297.
169. Souabni A., Cobaleda C., Schebesta M., Busslinger M. Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity 2002, 17:781-793.
170. Sriuranpong V., Borges M.W., Ravi R.K., Arnold D.R., Nelkin B.D., Baylin S.B., et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Research 2001, 61:3200-3205.
171. Sriuranpong V., Borges M.W., Strock C.L., Nakakura E.K., Watkins D.N., Blaumueller C.M., et al. Notch signaling induces rapid degradation of achaete-scute homolog 1. Molecular and Cell Biology 2002, 22:3129-3139.
172. Stahl M., Uemura K., Ge C., Shi S., Tashima Y., Stanley P. Roles of Pofut1 and O-fucose in mammalian Notch signaling. The Journal of Biological Chemistry 2008, 283:13638-13651.
173. Suchting S., Freitas C., Le Noble F., Benedito R., Breant C., Duarte A., et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:3225-3230.
174. Tanigaki K., Kuroda K., Han H., Honjo T. Regulation of B cell development by Notch/RBP-J signaling. Seminars in Immunology 2003, 15:113-119.
175. Thurston G., Noguera-Troise I., Yancopoulos G.D. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nature Reviews Cancer 2007, 7:327-331.
176. Tohda S., Kogoshi H., Murakami N., Sakano S., Nara N. Diverse effects of the Notch ligands Jagged1 and Delta1 on the growth and differentiation of primary acute myeloblastic leukemia cells. Experimental Hematology 2005, 33:558-563.
177. Tohda S., Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leukemia & Lymphoma 2001, 42:467-472.
178. Troen G., Wlodarska I., Warsame A., Hernandez Llodra S., De Wolf-Peeters C., Delabie J. NOTCH2 mutations in marginal zone lymphoma. Haematologica 2008, 93:1107-1109.
179. van Es J.H., van Gijn M.E., Riccio O., van den Born M., Vooijs M., Begthel H., et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435:959-963.
180. van Tetering G., van Diest P., Verlaan I., van der Wall E., Kopan R., Vooijs M. Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. The Journal of Biological Chemistry 2009, 284:31018-31027.
181. Viatour P., Ehmer U., Saddic L.A., Dorrell C., Andersen J.B., Lin C., et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. The Journal of Experimental Medicine 2011, 208:1963-1976.
182. Wallberg A.E., Pedersen K., Lendahl U., Roeder R.G. p300 and PCAF act cooperatively to mediate transcriptional activation from chromatin templates by notch intracellular domains in vitro. Molecular and Cellular Biology 2002, 22:7812-7819.
183. Wang Z., Banerjee S., Li Y., Rahman K.M., Zhang Y., Sarkar F.H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Research 2006, 66:2778-2784.
184. Wang Z., Zhang Y., Banerjee S., Li Y., Sarkar F.H. Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. International Journal of Cancer 2006, 118:1930-1936.
185. Wang Z., Zhang Y., Banerjee S., Li Y., Sarkar F.H. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 2006, 106:2503-2513.
186. Wang Z., Zhang Y., Li Y., Banerjee S., Liao J., Sarkar F.H. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Molecular Cancer Therapeutics 2006, 5:483-493.
187. Wang Z., Azmi A.S., Ahmad A., Banerjee S., Wang S., Sarkar F.H., et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Research 2009, 69:2757-2765.
188. Wang Z., Li Y., Banerjee S., Sarkar F.H. Emerging role of Notch in stem cells and cancer. Cancer Letters 2009, 279:8-12.
189. Wang J., Wakeman T.P., Lathia J.D., Hjelmeland A.B., Wang X.F., White R.R., et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2009, 28:17-28.
190. Wang Y.C., He F., Feng F., Liu X.W., Dong G.Y., Qin H.Y., et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Research 2010, 70:4840-4849.
191. Wang N.J., Sanborn Z., Arnett K.L., Bayston L.J., Liao W., Proby C.M., et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:17761-17766.
192. Weijzen S., Rizzo P., Braid M., Vaishnav R., Jonkheer S.M., Zlobin A., et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nature Medicine 2002, 8:979-986.
193. Weng A.P., Ferrando A.A., Lee W., Morris J.P.t., Silverman L.B., Sanchez-Irizarry C., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
194. Weng A.P., Millholland J.M., Yashiro-Ohtani Y., Arcangeli M.L., Lau A., Wai C., et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes & Development 2006, 20:2096-2109.
195. Weng A.P., Nam Y., Wolfe M.S., Pear W.S., Griffin J.D., Blacklow S.C., et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Molecular and Cellular Biology 2003, 23:655-664.
196. Westhoff B., Colaluca I.N., D'Ario G., Donzelli M., Tosoni D., Volorio S., et al. Alterations of the Notch pathway in lung cancer. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:22293-22298.
197. Wharton K.A., Yedvobnick B., Finnerty V.G., Artavanis-Tsakonas S. opa: a novel family of transcribed repeats shared by the Notch locus and other developmentally regulated loci in D. melanogaster. Cell 1985, 40:55-62.
198. Wilkin M.B., Carbery A.M., Fostier M., Aslam H., Mazaleyrat S.L., Higgs J., et al. Regulation of notch endosomal sorting and signaling by Drosophila Nedd4 family proteins. Current Biology 2004, 14:2237-2244.
199. Wilson J.J., Kovall R.A. Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA. Cell 2006, 124:985-996.
200. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. The Journal of Biological Chemistry 2004, 279:12876-12882.
201. Wu L., Griffin J.D. Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. Seminars in Cancer Biology 2004, 14:348-356.
202. Wu Y., Cain-Hom C., Choy L., Hagenbeek T.J., de Leon G.P., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464:1052-1057.
203. Yan M., Callahan C.A., Beyer J.C., Allamneni K.P., Zhang G., Ridgway J.B., et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010, 463:E6-7.
204. Yan M., Plowman G.D. Delta-like 4/Notch signaling and its therapeutic implications. Clinical Cancer Research 2007, 13:7243-7246.
205. Yao J., Qian C. Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway. Medical Oncology 2009, 27:1017-1022.
206. Zayzafoon M., Abdulkadir S.A., McDonald J.M. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. Journal of Biological Chemistry 2004, 279:3662-3670.
207. Zeng Q., Li S., Chepeha D.B., Giordano T.J., Li J., Zhang H., et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005, 8:13-23.
208. Zheng Q., Qin H., Zhang H., Li J., Hou L., Wang H., et al. Notch signaling inhibits growth of the human lung adenocarcinoma cell line A549. Oncology Reports 2007, 17:847-852.
209. Zhu T.S., Costello M.A., Talsma C.E., Flack C.G., Crowley J.G., Hamm L.L., et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Research 2011, 71:6061-6072.
210. Zweidler-McKay P.A., He Y., Xu L., Rodriguez C.G., Karnell F.G., Carpenter A.C., et al. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 2005, 106:3898-3906.